Sickle cell disease (SCD) in pregnancy can be associated with adverse maternal and perinatal outcomes. Furthermore, complications of SCD can be aggravated by pregnancy. Optimal prenatal care aims to decrease the occurrence of maternal and fetal complications. A retrospective, French, twocenter study compared two care strategies for pregnant women with SCD over two time periods. In the first study period (2005)(2006)(2007)(2008)(2009)(2010), the women were systematically offered prophylactic transfusions. In the second study period (2011-2014), a targeted transfusion strategy was applied whenever possible, and home-based prophylactic nocturnal oxygen therapy was offered to all the pregnant women. The two periods did not differ significantly in terms of the incidence of vaso-occlusive events. Maternal mortality, perinatal mortality, and obstetric complication rates were also similar in the two periods, as was the incidence of post-transfusion complications (6.1% in 2005-2010 and 1.3% in 2011-2014, P 5 .15), although no de novo alloimmunizations or delayed hemolysis transfusion reactions were observed in the second period. The results of this preliminary, retrospective Myriam Labopin and Aur elie Stanislas contributed equally.
Due to improvements in the management of SCD patients, over 95% of affected infants survive to adulthood in industrialized countries.
Therefore, the number of women reaching reproductive age is increasing. 1 In France, more than 300 pregnancies in women with SCD are recorded every year, and pregnancy is known to aggravate the complications of SCD. The maternal risks include prepartum and postpartum VOCs, urinary tract infections, pulmonary complications, anemia, thromboembolic events, hypertensive disorders, and death 2 ; these complications may even affect women who only display mild symptoms before pregnancy (including HbSC patients). 3 Despite the steady decrease in the mortality rate for pregnant women with SCD since the 1970s, 1 several studies over the last two decades have reported poor outcomes for SCD pregnancies. 4 A recent
French study showed that between 1996 and 2009, the risk of maternal death was approximately 50 times higher in women with SCD than that in the general population. 5 The fetal morbidity rate is also higher in women with SCD than that in the general population; fetal growth retardation and induced and spontaneous prematurity are the most common risks. Furthermore, the perinatal mortality rate (up to three months of age) is higher in babies born to women with SCD. 6 The lack of randomized, clinical studies of pregnant women with SCD complicates the development of evidence-based care strategies. Consequently, care is often based on retrospective findings and expert opinions. 7, 8 RBC transfusion and careful prevention of infections represent the only available treatments in this setting. Two different transfusion policies have been proposed. First, prophylactic blood transfusions are intended to provide stable, long-term correction of severe anemia and sickling in both the maternal and placental circulation. 9 Second, therapeutic blood transfusions are initiated only if certain SCD-related adverse events or obstetric complications arise and/or if a woman has a history of organ failure.
The studies that prompted the recommendation of prophylactic transfusions for pregnant women with SCD were biased by the absence of randomization, 10 whereas the only prospective study performed to date failed to show evidence of any benefit for maternal and neonatal outcomes with this strategy (relative to selective transfusion) and concluded that it should not be used without clear indications. 11 In fact, the last study performed in France on systematic prophylactic transfusion in pregnant SCD women showed that the proportion of VOCs was the same as that in patients who were not systematically transfused.
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Post-transfusion alloimmunization 13 and delayed hemolytic transfusion reactions (DHTRs) are frequent complications of transfusion during SCD pregnancies that can indirectly affect the newborn by inducing hypoxia and may ultimately prevent the woman from receiving further transfusions. 14, 15 Post-transfusion complications represent negative prognostic factors that affect both the mother's health and fetal development, thus increasing the risk of premature death.
Pregnancy outcomes are also complicated by the elevated levels of oxygen required to satisfy the increased metabolic demands of the placenta and fetus. Furthermore, pregnant women are at an increased risk of sleep-disordered breathing (SDB) due to the physiologic changes in pregnancy as evidenced by a high prevalence of snoring in gravidas.
Patients with baseline hypoxemia or asthma have been reported to experience more severe SCA complications [16] [17] [18] [19] and (in some studies) pain crises. 16, 18, [20] [21] [22] Interestingly, SDB (including snoring and OSA)
has been linked to adverse pregnancy outcomes (such as gestational hypertension 19, 23, 24 and gestational diabetes) 23, 25 and potential adverse fetal outcomes (such as preterm birth 23, 24, 26 and growth restriction). 27 Considering these observations, the first innovative approach that we introduced was the widespread use of prophylactic oxygen treatment at home during the night and/or during daytime rest periods. This innovative treatment was initiated based on very preliminary observations in the preceding years, i.e., the clinical benefit observed in some pregnant women with an extensive obstetric history and significant contraindications to transfusion. Moreover, some data in the literature supported our hypothesis and advocated prophylactic oxygen therapy at home, 16, [20] [21] [22] [28] [29] [30] [31] as no potential negative impact on erythropoiesis or erythropoietin production was identified. 32, 33 This strategy was also prompted by the results of experiments in an SCD mouse model in which a high-oxygen environment during pregnancy was associated with a lower prenatal fetal/maternal mortality rate. 34 Therefore, the two main objectives of the present retrospective study were to (i) evaluate the potential clinical benefits of the widespread use of prophylactic nocturnal oxygen treatment at home and (ii) identify prognostic factors that influence the complication rate in pregnant women with SCD.
| M ET HOD S
We performed a retrospective cohort study based on analysis of electronic and paper-based medical records and hospital admission records. The study database is available on request.
| Patient care
The care team included a senior hematologist, an obstetrician, an infectious disease specialist, and specially trained midwives. We followed the guidelines issued by the French Reference Center for Major Sickle
Cell Syndromes for the care and management of SCD patients. 35 Consultations were scheduled monthly during the first trimester, fortnightly after 24 WA, and weekly after 36 WA. Ultrasound scans were performed at 21-24 WA and between 32-34 WA, as recommended in
France. To screen for intrauterine growth retardation (IUGR), two additional scans were performed at 28 and 36 weeks. In the last month of pregnancy, the women were admitted to the obstetric department's day hospital once a week to monitor fetal well-being and plan the delivery. The mode of delivery was selected based on the woman's obstetric history, existing chronic SCD complications, and general condition at the end of pregnancy.
The following data were recorded on the e-CRF for each patient: VOCs during hospitalization and is not associated with hypercapnic side effects. We provided nose pieces that were appropriately sized for each patient's face and never used masks. In fact, the minimum oxygen flow rate for a mask is 6 L/min; lower flow rates are associated with insufficient oxygen delivery and increased re-inhalation of carbon dioxide.
The company supplying the home oxygen condenser (VitalAire, Vitry-sur-Seine, France) provided information on the frequency of use (including nights per week, hours per night, and the flow rate).
This information was relayed to the patients during a patient education program that included home visits by technicians. The technicians verified the patients' compliance with treatment and safety instructions and helped personalize the device (selection of appropriate nose pieces and humidifiers, etc.). A visit was scheduled every 3 months, and the patient's referring physician always received a copy of the report.
Furthermore, we instructed the patients to use oxygen therapy primarily at night because (i) this is when the upper respiratory tract is most vulnerable congestion and low oxygen saturation, and (ii) we did not intend to increase the amount of time spent resting during the day, which is not often practical and can also lead to the occurrence of adverse events in pregnant women. We did not perform sleep analyzes before or after the initiation of oxygen therapy.
At each consultation, the patient was asked about her use of prophylactic oxygen therapy at home and was reminded of the treatment instructions.
The Information Table S2 ).
| Statistical analysis
Before pregnancy, 23% of the patients had received a long-term treatment (hydroxyurea (HU) or transfusion (Supporting Information   Table S2 )); 27% were still receiving HU (Supporting Information Table   S2 ), 16% had discontinued treatment before pregnancy, and 11% had discontinued treatment only when the pregnancy was discovered (after a mean (range) time interval of 10 WA (4-28)). In 17 cases, the patients were on a long-term, prophylactic transfusion regimen (initiated before pregnancy) for SCD complications that was continued during and after pregnancy. More than 14.1% of the cases had a history of transfusionrelated complications: 9.4% had developed severe alloimmunization, 6.3% had experienced DHTRs, and 5.8% had a rare blood group.
Voluntary termination of pregnancy was reported for 31.1% of the patients. The obstetric data showed that 23% of the cases were primigravida and 41.9% were nulliparous. The mean (range) gravidity and parity values were 2.97 (1-9) and 0.91 (0-5), respectively. More than 9.4% of the patients had a history of poor obstetric outcomes, with late miscarriage in 2.6% of the patients and IUFD in 6.8% of the patients; however, no perinatal deaths were reported. Cesarean section was reported for 40.4% of the patients who had already given birth (Supporting Information Table S3 ). 
| Pregnancy follow-up, treatment, and morbidity
During the first study period (2005-2010), 115 pregnancies were monitored in our two reference centers (Supporting Information Table   S1 ). Consistent with the French national guidelines, a prophylactic transfusion program was applied in 67% of the cases. Notably, prophylactic transfusion was contraindicated in 13% of the cases. 
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The change in treatment strategy was not associated with a 52.6% in 2011-2014; P 5 .08) ( Table 1 ).
Obstetric complication rates were similar in the two periods, including those related to hypertensive disorders (including pregnancyinduced hypertension, pre-eclampsia, eclampsia, and HELLP syndrome: (Table 1) . Notably, we did not observe 41 The changes in our treatment strategy (including prophylactic oxygen therapy) were associated with a clear decrease in the transfusion rate, which was not related to a difference in maternal SCD events.
We were very pleased to observe the absence of any de novo alloimmunizations or DHTRs during the 2011-2014 period. The only case of DHTR involved a patient with a history of this type of event; however, the patient was experiencing a life-threatening ACS and therefore, despite the very high risk of relapse, transfusion was essential.
Although prophylactic oxygen therapy was not expected to influence the pathophysiology of alloimmunization and DHTR, the significant decrease in the occurrence of these complications is correlated with the decrease in the transfusion burden, which is subsequently related to the overall frequency of SCD complications.
Unfortunately, the patients' compliance with prophylactic home oxygen therapy during pregnancy and overnight pulse oximetry (to detect nocturnal hypoxemia) before the introduction of this treatment were not assessed systematically, which prevented us from analyzing a putative improvement in oxygenation with prophylactic oxygen therapy in this subgroup of women. Importantly, we did not observe any severe maternal-fetal adverse events related to prophylactic oxygen therapy. The patients' selfreported tolerance was excellent, which led us to offer this treatment systematically as of 2011.
No definitive conclusion can be drawn from this retrospective study of two concomitant changes in our treatment strategy (i.e., targeted transfusion and prophylactic oxygen therapy). The methodological limitation of retrospective studies was highlighted in a recent metaanalysis by Malinowski et al. 42 Considering this limitation, we have set up a prospective, multicenter, randomized clinical trial (RCT) of prophylactic oxygen therapy during SCD pregnancies (NCT02813850). In fact,
we hypothesize that prophylactic oxygen therapy relieves the symptoms of SCD (particularly during pregnancy). Accordingly, we intend to determine whether an independent effect on treatment outcomes exists in this high-risk medical setting. The study will investigate whether prophylactic oxygen therapy will decrease (i) the transfusion requirement and (ii) the incidence of severe post-transfusion complications without increasing the incidence of VOCs or obstetric complications. If this endpoint is met, prophylactic oxygen therapy may be of major value, especially in regions with sub-optimal transfusion safety.
All the pregnant women with SCD in this ongoing RCT will undergo oximetry measurements for two consecutive nights so that we can establish whether the results are significant in a hypoxic subgroup only.
The use of prophylactic home oxygen therapy in SCD appears to be promising as (i) our patients currently request this new treatment option (despite its constraints), (ii) the preliminary results in previous studies have been positive, 33, 43 and (iii) a pilot study of morbidity prevention in SCD by overnight supplementary oxygen has recently been initiated. 44 Our results are consistent with several previous reports, as confirmed by a recent meta-analysis 45 Syndromes. 47 The results of the present study also highlighted several risk factors, such as patient age, nulliparity, and a history of VOCs and longterm therapy, for pregnant women with SCD. Our forthcoming prospective multicenter RCT should also enable us to establish a severity score and therefore adapt the therapeutic strategy according to a patient's risk factors.
